Search
Kazia Therapeutics Ltd
KZIAAdd to Watchlist
13.250USD
-0.140-1.05%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
107.25MMarket Cap
LossP/E TTM
More Details of Kazia Therapeutics Ltd Company
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd Info
Ticker SymbolKZIA
Company nameKazia Therapeutics Ltd
IPO dateSep 01, 1994
CEOFriend (John E)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endSep 01
AddressThree International Towers Level 24,
CitySYDNEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2000
Phone1161298780088
Websitehttps://www.kaziatherapeutics.com/
Ticker SymbolKZIA
IPO dateSep 01, 1994
CEOFriend (John E)
Company Executives of Kazia Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
FAQs
Who are the top five shareholders of Kazia Therapeutics Ltd?
The top five shareholders of Kazia Therapeutics Ltd are: Mr. Steven Roy Stent (Steve) Coffey
How many institutions hold shares of Kazia Therapeutics Ltd (KZIA)?
As of 2026Q1, 50 institutions hold shares of Kazia Therapeutics Ltd, with a combined market value of approximately 3.97M, accounting for 36.96% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3572773.00.